查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1679373

全球多巴胺促效劑市場：市場規模、市場佔有率、趨勢分析（按藥物、給藥途徑、應用、分銷管道和地區）、按細分市場預測（2025-2030 年）

Dopamine Agonist Market Size, Share & Trends Analysis Report By Drug (Non-ergot Dopamine Agonists, Ergot Alkaloids), By Route Of Administration (Oral, Injectable), By Application, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 153 Pages | 商品交期: 2-10個工作天內

價格

多巴胺促效劑市場的成長與趨勢：

根據 Grand View Research, Inc. 的最新報告，全球多巴胺促效劑市場規模預計到 2030 年將達到 18.3 億美元，預測期內的複合年成長率為 5.70%。神經系統治療對多巴胺促效劑（包括麥角生物鹼和非麥角多巴胺促效劑）的需求為製藥業創造了重大機會。這些藥物已被證明可有效治療帕金森氏症、不安腿症候群（RLS）和高催乳素血症等疾病，正在推動市場擴張。儘管麥角衍生的多巴胺促效劑早已在臨床上使用，但非麥角多巴胺促效劑由於安全性和耐受性的改善而越來越受到青睞。隨著支持多巴胺促效劑療效的臨床證據不斷增加，促效劑在治療運動障礙的應用也日益增加。

口服和注射製劑的開發進一步擴大了治療的機會和患者的偏好。口服多巴胺促效劑廣泛用於治療巴金森氏症和RLS等慢性病，具有給藥方便、長期堅持等特性。另一方面，注射劑在疾病的急性和晚期的治療中發揮重要作用，需要立即產生持久的效果。隨著製藥公司專注於開發創新的藥物輸送方法，市場將進一步成長。

Teva Pharmaceutical Industries Ltd.、GSK plc.、Supernus Pharmaceuticals, Inc.、H. Lundbeck A/S、Amneal Pharmaceuticals LLC、UCB Pharma、Novartis AG、VeroScience LLC.、Pfizer Inc. 和 Boehringer Ingelheim Pharmaceuticals, Inc. 等製藥公司正在積極為擴張市場擴張市場做出貢獻。這些公司致力於研究和開發，以提高療效、安全性和患者依從性，進一步促進這些治療方法的採用。

零售藥局在多巴胺激動劑的分銷中發揮越來越重要的作用，特別是用於慢性病管理的口服促效劑。這些藥局不僅提供便利的藥物取得管道，還提供病患教育和諮詢服務，以確保病患依從性和最佳治療效果。零售藥局是長期患者照護的關鍵組成部分，因為它們可以提供持續的藥物補充和支持。

密切監測至關重要，特別是在治療的早期階段。例如，帕金森氏症患者通常在醫院的監督下開始接受治療，然後才轉入門診治療。隨著患者病情穩定，零售藥局和專科藥局成為持續用藥和支持服務的主要資訊來源，而不會中斷慢性神經系統疾病的治療。

隨著多巴胺促效劑的需求不斷增加，供應鏈管理和藥品分銷等挑戰也隨之出現。確保口服和注射藥物的穩定供應需要強大的物流基礎設施和注重病患教育，以最大限度地提高依從性和治療效果。此外，持續對研發的投資，特別是在新型給藥系統的研發上，為製藥公司提供了滿足更廣泛患者群體和改善治療效果的機會。

多巴胺促效劑市場：概述

  • 2024 年，非麥角多巴胺促效劑佔據市場主導地位，鞏固了其作為神經系統疾病首選治療方案的地位。其良好的安全性、增強的耐受性和不斷提高的臨床接受度使其成為同類藥物中的領先治療方法。
  • 到 2024 年，口服藥物將佔據市場主導地位。口服製劑因其方便、長期堅持的優勢以及對治療帕金森氏症、不安腿綜合症（RLS）和高催乳素血症等慢性病的有效效果而受到廣泛青睞。
  • 到 2024 年，零售藥局將成為主要分銷管道。零售藥局提供的服務更加便捷，易於獲取，使其成為使用多巴胺促效劑的患者的主要網路基地台。
  • 北美憑藉其發達的醫療保健基礎設施、對神經系統疾病的高度認知以及先進的治療方案而引領市場。

目錄

第1章 分析方法及範圍

第 2 章執行摘要

3. 多巴胺促效劑市場：變數、趨勢和範圍

  • 母市場展望
  • 附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
  • 多巴胺促效劑市場：分析工具
    • 波特五力分析
    • PESTEL 分析
  • 管道分析
    • 第 1 階段
    • 第 2 階段
    • 第 3 階段

第 4 章 多巴胺促效劑市場：藥物特定估計與趨勢分析

  • 多巴胺促效劑市場：細分儀表板（按藥物）
  • 多巴胺促效劑市場：藥物趨勢分析（2024 年和 2030 年）
  • 非麥角多巴胺促效劑
  • 麥角生物鹼

第 5 章 多巴胺促效劑市場：按應用的估計和趨勢分析

  • 多巴胺促效劑市場：細分儀表板、按應用分類
  • 多巴胺促效劑市場：按應用分類的趨勢分析（2024 年和 2030 年）
  • 帕金森氏症
  • 不寧腿(RLS)
  • 高催乳素血症
  • 其他

第6章 多巴胺促效劑市場：依給藥途徑的估計與趨勢分析

  • 多巴胺促效劑市場：細分儀表板，依給藥途徑分類
  • 多巴胺促效劑市場：按給藥途徑分類的趨勢分析（2024 年和 2030 年）
  • 口服
  • 注射
  • 其他

第 7 章 多巴胺促效劑市場：按分銷管道進行的估計和趨勢分析

  • 多巴胺促效劑市場：細分儀表板、通路
  • 多巴胺促效劑市場：按分銷管道分類的趨勢分析（2024 年和 2030 年）
  • 零售藥局
  • 醫院藥房
  • 其他藥局

第 8 章 多巴胺促效劑市場：按地區分類的估計和趨勢分析

  • 多巴胺促效劑市場佔有率（按地區分類） (2024 年和 2030 年)
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司分類
  • 參與企業概況
  • 財務表現
  • 產品基準評效
  • 公司市場佔有率分析（2024 年）
  • 公司簡介
    • Teva Pharmaceutical Industries Ltd
    • GSK plc.
    • Supernus Pharmaceuticals, Inc.
    • H. Lundbeck A/S
    • Amneal Pharmaceuticals LLC
    • UCB Pharma
    • Novartis AG
    • VeroScience LLC.
    • Pfizer Inc.
    • Boehringer Ingelheim Pharmaceuticals, Inc.

第 10 章 結論

Product Code: GVR-4-68040-531-1

Dopamine Agonist Market Growth & Trends:

The global dopamine agonist market size is anticipated to reach USD 1.83 billion by 2030 and is projected to grow at a CAGR of 5.70% during the forecast period, according to a new report by Grand View Research, Inc. The demand for dopamine agonists in neurological treatments, including ergot alkaloids and non-ergot dopamine agonists, is creating significant opportunities in the pharmaceutical sector. These drugs, which have demonstrated effectiveness in managing conditions like Parkinson's disease, restless legs syndrome (RLS), and hyperprolactinemia, are driving market expansion. Ergot-derived dopamine agonists have long been used in clinical practice, while non-ergot dopamine agonists are gaining preference due to their improved safety profiles and tolerability. With growing clinical evidence supporting their efficacy, the acceptance of dopamine agonists in managing movement disorders continues to rise.

The development of oral and injectable formulations further broadens treatment accessibility and patient preference. Oral dopamine agonists are widely used for chronic conditions like Parkinson's disease and RLS, allowing for convenient administration and long-term adherence. Injectable formulations, on the other hand, play a crucial role in managing acute or advanced-stage cases where immediate and sustained drug action is required. With pharmaceutical companies focusing on developing innovative drug delivery methods, the market is poised for further growth.

Pharmaceutical companies such as Teva Pharmaceutical Industries Ltd., GSK plc., Supernus Pharmaceuticals, Inc., H. Lundbeck A/S, Amneal Pharmaceuticals LLC, UCB Pharma, Novartis AG, VeroScience LLC., Pfizer Inc., and Boehringer Ingelheim Pharmaceuticals, Inc. are actively contributing to the expansion of the market. These companies are engaged in research and development efforts to improve drug efficacy, safety, and patient compliance, further driving the adoption of these therapies.

Retail pharmacies play an increasing role in the distribution of dopamine agonists, particularly for oral formulations used in chronic disease management. These pharmacies offer not only easy access to medications but also patient education and counseling services to ensure adherence and optimal treatment outcomes. The ability of retail pharmacies to provide consistent medication refills and support makes them a key component in long-term patient care.

Hospital pharmacies remain crucial, especially in the initial stages of treatment, when close monitoring is essential. Parkinson's disease patients, for instance, often begin therapy under hospital supervision before transitioning to outpatient care. As patients stabilize, retail and specialty pharmacies become primary sources for continued medication access and support services, ensuring uninterrupted treatment for chronic neurological disorders.

As the demand for dopamine agonists continues to rise, challenges such as supply chain management and drug distribution will emerge. Ensuring the consistent availability of both oral and injectable therapies will require a strong logistics infrastructure and a focus on patient education to maximize adherence and therapeutic outcomes. Moreover, continued investment in research and development, particularly for novel delivery systems, presents an opportunity for pharmaceutical companies to cater to a broader patient population and enhance treatment effectiveness.

Dopamine Agonist Market Report Highlights:

  • In 2024, non-ergot dopamine agonists dominated the market, solidifying their position as the preferred treatment option for neurological disorders. Their superior safety profile, improved tolerability, and growing clinical acceptance make them the leading therapy in this class.
  • The oral segment dominated the market in 2024. Oral formulations are widely preferred due to their convenience, long-term adherence benefits, and effectiveness in managing chronic conditions like Parkinson's disease, restless legs syndrome (RLS), and hyperprolactinemia.
  • Retail pharmacies emerged as the dominant distribution channel in 2024. The growing convenience and accessibility offered by retail pharmacies made them the primary point of access for patients using dopamine agonist medications.
  • North America led the market, attributed to factors such as a well-established healthcare infrastructure, high awareness of neurological disorders, and the availability of advanced treatment options.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Dopamine Agonist Market Variables, Trends, & Scope

  • 3.1. Parent Market Outlook
  • 3.2. Ancillary Market Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
      • 3.3.1.1. Rising prevalence of neurological disorders
      • 3.3.1.2. Growing geriatric population
      • 3.3.1.3. Advancements in drug formulations & delivery methods
    • 3.3.2. Market Restraints Analysis
      • 3.3.2.1. Severe side effects & safety concerns
      • 3.3.2.2. Emerging alternative therapies
  • 3.4. Dopamine Agonist Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape
  • 3.5. Pipeline Analysis
    • 3.5.1. Phase 1
    • 3.5.2. Phase 2
    • 3.5.3. Phase 3

Chapter 4. Dopamine Agonist Market: By Drug Estimates & Trend Analysis

  • 4.1. Dopamine Agonist Market: Drug Segment Dashboard
  • 4.2. Dopamine Agonist Market: By Drug Movement Analysis, 2024 & 2030 (USD Million)
  • 4.3. Non-Ergot Dopamine Agonists
    • 4.3.1. Non-Ergot Dopamine Agonists Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Ergot Alkaloids
    • 4.4.1. Ergot Alkaloids Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Dopamine Agonist Market: Application Estimates & Trend Analysis

  • 5.1. Dopamine Agonist Market: Application Segment Dashboard
  • 5.2. Dopamine Agonist Market: By Application Movement Analysis, 2024 & 2030 (USD Million)
  • 5.3. Parkinson's Disease
    • 5.3.1. Parkinson's Disease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Restless Legs Syndrome (RLS)
    • 5.4.1. Restless Legs Syndrome (RLS) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Hyperprolactinemia
    • 5.5.1. Hyperprolactinemia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Dopamine Agonist Market: Route of Administration Estimates & Trend Analysis

  • 6.1. Dopamine Agonist Market: Route of Administration Segment Dashboard
  • 6.2. Dopamine Agonist Market: By Route of Administration Movement Analysis, 2024 & 2030 (USD Million)
  • 6.3. Oral
    • 6.3.1. Oral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Injectable
    • 6.4.1. Injectable Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Others
    • 6.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Dopamine Agonist Market: Distribution Channel Estimates & Trend Analysis

  • 7.1. Dopamine Agonist Market: Distribution Channel Segment Dashboard
  • 7.2. Dopamine Agonist Market: Distribution Channel Movement Analysis, 2024 & 2030 (USD Million)
  • 7.3. Retail Pharmacies
    • 7.3.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Hospital Pharmacies
    • 7.4.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Other Pharmacies
    • 7.5.1. Other Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Dopamine Agonist Market: Regional Estimates & Trend Analysis

  • 8.1. Dopamine Agonist Market Share, By Region, 2024 & 2030 (USD Million)
  • 8.2. North America
    • 8.2.1. North America Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. Key Country Dynamics
      • 8.2.2.2. Target Disease Prevalence
      • 8.2.2.3. Regulatory Framework
      • 8.2.2.4. Reimbursement Framework
      • 8.2.2.5. U.S. Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.3. Canada
      • 8.2.3.1. Key Country Dynamics
      • 8.2.3.2. Target Disease Prevalence
      • 8.2.3.3. Regulatory Framework
      • 8.2.3.4. Reimbursement Framework
      • 8.2.3.5. Canada Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.4. Mexico
      • 8.2.4.1. Key Country Dynamics
      • 8.2.4.2. Target Disease Prevalence
      • 8.2.4.3. Regulatory Framework
      • 8.2.4.4. Reimbursement Framework
      • 8.2.4.5. Mexico Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3. Europe
    • 8.3.1. Europe Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.2. UK
      • 8.3.2.1. Key Country Dynamics
      • 8.3.2.2. Target Disease Prevalence
      • 8.3.2.3. Regulatory Framework
      • 8.3.2.4. Reimbursement Framework
      • 8.3.2.5. Uk Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.3. Germany
      • 8.3.3.1. Key Country Dynamics
      • 8.3.3.2. Target Disease Prevalence
      • 8.3.3.3. Regulatory Framework
      • 8.3.3.4. Reimbursement Framework
      • 8.3.3.5. Germany Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.4. France
      • 8.3.4.1. Key Country Dynamics
      • 8.3.4.2. Target Disease Prevalence
      • 8.3.4.3. Regulatory Framework
      • 8.3.4.4. Reimbursement Framework
      • 8.3.4.5. France Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.5. Italy
      • 8.3.5.1. Key Country Dynamics
      • 8.3.5.2. Target Disease Prevalence
      • 8.3.5.3. Regulatory Framework
      • 8.3.5.4. Reimbursement Framework
      • 8.3.5.5. Italy Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.6. Spain
      • 8.3.6.1. Key Country Dynamics
      • 8.3.6.2. Target Disease Prevalence
      • 8.3.6.3. Regulatory Framework
      • 8.3.6.4. Reimbursement Framework
      • 8.3.6.5. Spain Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.7. Denmark
      • 8.3.7.1. Key Country Dynamics
      • 8.3.7.2. Target Disease Prevalence
      • 8.3.7.3. Regulatory Framework
      • 8.3.7.4. Reimbursement Framework
      • 8.3.7.5. Denmark Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.8. Sweden
      • 8.3.8.1. Key Country Dynamics
      • 8.3.8.2. Target Disease Prevalence
      • 8.3.8.3. Regulatory Framework
      • 8.3.8.4. Reimbursement Framework
      • 8.3.8.5. Sweden Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.9. Norway
      • 8.3.9.1. Key Country Dynamics
      • 8.3.9.2. Target Disease Prevalence
      • 8.3.9.3. Regulatory Framework
      • 8.3.9.4. Reimbursement Framework
      • 8.3.9.5. Norway Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.2. Japan
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Target Disease Prevalence
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Reimbursement Framework
      • 8.4.2.5. Japan Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. China
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Reimbursement Framework
      • 8.4.3.5. China Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. India
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Reimbursement Framework
      • 8.4.4.5. India Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.5. Australia
      • 8.4.5.1. Key Country Dynamics
      • 8.4.5.2. Target Disease Prevalence
      • 8.4.5.3. Regulatory Framework
      • 8.4.5.4. Reimbursement Framework
      • 8.4.5.5. Australia Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.6. South Korea
      • 8.4.6.1. Key Country Dynamics
      • 8.4.6.2. Target Disease Prevalence
      • 8.4.6.3. Regulatory Framework
      • 8.4.6.4. Reimbursement Framework
      • 8.4.6.5. South Korea Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.7. Thailand
      • 8.4.7.1. Key Country Dynamics
      • 8.4.7.2. Target Disease Prevalence
      • 8.4.7.3. Regulatory Framework
      • 8.4.7.4. Reimbursement Framework
      • 8.4.7.5. Thailand Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Latin America
    • 8.5.1. Latin America Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.2. Brazil
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Target Disease Prevalence
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Reimbursement Framework
      • 8.5.2.5. Japan Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. Argentina
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Reimbursement Framework
      • 8.5.3.5. China Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Middle East and Africa
    • 8.6.1. Middle East and Africa Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.2. South Africa
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Target Disease Prevalence
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Reimbursement Framework
      • 8.6.2.5. South Africa Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. Saudi Arabia
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Target Disease Prevalence
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Reimbursement Framework
      • 8.6.3.5. Saudi Arabia Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. UAE
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Target Disease Prevalence
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. Reimbursement Framework
      • 8.6.4.5. UAE Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. Kuwait
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Target Disease Prevalence
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Reimbursement Framework
      • 8.6.5.5. Kuwait Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis by Key Market Participants
  • 9.2. Company Categorization
  • 9.3. Participant Overview
  • 9.4. Financial Performance
  • 9.5. Product Bench Marking
  • 9.6. Company Market Share Analysis, 2024
  • 9.7. Company Profiles
    • 9.7.1. Teva Pharmaceutical Industries Ltd
      • 9.7.1.1. Participant's Overview
      • 9.7.1.2. Financial Performance
      • 9.7.1.3. Product Benchmarking
      • 9.7.1.4. Recent Developments/ Strategic Initiatives
    • 9.7.2. GSK plc.
      • 9.7.2.1. Participant's Overview
      • 9.7.2.2. Financial Performance
      • 9.7.2.3. Product Benchmarking
      • 9.7.2.4. Recent Developments/ Strategic Initiatives
    • 9.7.3. Supernus Pharmaceuticals, Inc.
      • 9.7.3.1. Participant's Overview
      • 9.7.3.2. Financial Performance
      • 9.7.3.3. Product Benchmarking
      • 9.7.3.4. Recent Developments/ Strategic Initiatives
    • 9.7.4. H. Lundbeck A/S
      • 9.7.4.1. Participant's Overview
      • 9.7.4.2. Financial Performance
      • 9.7.4.3. Product Benchmarking
      • 9.7.4.4. Recent Developments/ Strategic Initiatives
    • 9.7.5. Amneal Pharmaceuticals LLC
      • 9.7.5.1. Participant's Overview
      • 9.7.5.2. Financial Performance
      • 9.7.5.3. Product Benchmarking
      • 9.7.5.4. Recent Developments/ Strategic Initiatives
    • 9.7.6. UCB Pharma
      • 9.7.6.1. Participant's Overview
      • 9.7.6.2. Financial Performance
      • 9.7.6.3. Product Benchmarking
      • 9.7.6.4. Recent Developments/ Strategic Initiatives
    • 9.7.7. Novartis AG
      • 9.7.7.1. Participant's Overview
      • 9.7.7.2. Financial Performance
      • 9.7.7.3. Product Benchmarking
      • 9.7.7.4. Recent Developments/ Strategic Initiatives
    • 9.7.8. VeroScience LLC.
      • 9.7.8.1. Participant's Overview
      • 9.7.8.2. Financial Performance
      • 9.7.8.3. Product Benchmarking
      • 9.7.8.4. Recent Developments/ Strategic Initiatives
    • 9.7.9. Pfizer Inc.
      • 9.7.9.1. Participant's Overview
      • 9.7.9.2. Financial Performance
      • 9.7.9.3. Product Benchmarking
      • 9.7.9.4. Recent Developments/ Strategic Initiatives
    • 9.7.10. Boehringer Ingelheim Pharmaceuticals, Inc.
      • 9.7.10.1. Participant's Overview
      • 9.7.10.2. Financial Performance
      • 9.7.10.3. Product Benchmarking
      • 9.7.10.4. Recent Developments/ Strategic Initiatives

Chapter 10. Conclusion

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 North America dopamine agonist market estimates and forecasts, by country, 2018 - 2030 (USD Million)
  • Table 4 North America dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 5 North America dopamine agonist market estimates and forecasts, by drug, 2018 - 2030 (USD Million)
  • Table 6 North America dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 7 North America dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 8 U.S. dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 9 U.S. dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
  • Table 10 U.S. dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 11 U.S. dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 12 Canada dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 13 Canada dopamine agonist market estimates and forecasts, by drug, 2018 - 2030 (USD Million)
  • Table 14 Canada dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 15 Canada dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 16 Mexico dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 17 Mexico dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
  • Table 18 Mexico dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 19 Mexico dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 20 Europe dopamine agonist market estimates and forecasts, by country, 2018 - 2030 (USD Million)
  • Table 21 Europe dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 22 Europe dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
  • Table 23 Europe dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 24 Europe dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 25 UK dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 26 UK dopamine agonist market estimates and forecasts, by drug, 2018 - 2030 (USD Million)
  • Table 27 UK dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 28 UK dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 29 Germany dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 30 Germany dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
  • Table 31 Germany dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 32 Germany dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 33 France dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 34 France dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
  • Table 35 France dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 36 France dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 37 Spain dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 38 Spain dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
  • Table 39 Spain dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 40 Spain dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 41 Italy dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 42 Italy dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
  • Table 43 Italy dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 44 Italy dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 45 Denmark dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 46 Denmark dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
  • Table 47 Denmark dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 48 Denmark dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 49 Sweden dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 50 Sweden dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
  • Table 51 Sweden dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 52 Sweden dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 53 Norway dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 54 Norway dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
  • Table 55 Norway dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 56 Norway dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific dopamine agonist market estimates and forecasts, by country, 2018 - 2030 (USD Million)
  • Table 58 Asia Pacific dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 59 Asia Pacific dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
  • Table 60 Asia Pacific dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 61 Asia Pacific dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 62 Japan dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 63 Japan dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
  • Table 64 Japan dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 65 Japan dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 66 China dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 67 China dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
  • Table 68 China dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 69 China dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 70 India dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 71 India dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
  • Table 72 India dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 73 India dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 74 South Korea dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 75 South Korea dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
  • Table 76 South Korea dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 77 South Korea dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 78 Australia dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 79 Australia dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
  • Table 80 Australia dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 81 Australia dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 82 Thailand dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 83 Thailand dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
  • Table 84 Thailand dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 85 Thailand dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 86 Latin America dopamine agonist market estimates and forecasts, by country, 2018 - 2030 (USD Million)
  • Table 87 Latin America dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 88 Latin America dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
  • Table 89 Latin America dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 90 Latin America dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 91 Brazil dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 92 Brazil dopamine agonist market estimates and forecasts, by drug, 2018 - 2030 (USD Million)
  • Table 93 Brazil dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 94 Brazil dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 95 Argentina dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 96 Argentina dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
  • Table 97 Argentina dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 98 Argentina dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 99 MEA dopamine agonist market estimates and forecasts, by country, 2018 - 2030 (USD Million)
  • Table 100 MEA dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 101 MEA dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
  • Table 102 MEA dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 103 MEA dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 104 South Africa dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 105 South Africa dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
  • Table 106 South Africa dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 107 South Africa dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 108 UAE dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 109 UAE dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
  • Table 110 UAE dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 111 UAE dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 112 Saudi Arabia dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 113 Saudi Arabia dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
  • Table 114 Saudi Arabia dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 115 Saudi Arabia dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 116 Kuwait dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 117 Kuwait dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
  • Table 118 Kuwait dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 119 Kuwait dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Dopamine agonist market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 QFD modelling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Application segment snapshot
  • Fig. 10 Drug and application segment snapshot
  • Fig. 11 Route of administration and distribution channel segment snapshot
  • Fig. 12 Competitive landscape snapshot
  • Fig. 13 Pharmaceutical market, (USD Billion)
  • Fig. 14 Market dynamics
  • Fig. 15 Porter's five forces analysis
  • Fig. 16 PESTLE analysis
  • Fig. 17 Dopamine agonist market: Drug outlook and key takeaways
  • Fig. 18 Dopamine agonist market: Drug movement analysis
  • Fig. 19 Ergot alkaloids market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Non-ergot dopamine agonists market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Dopamine agonist market: Application outlook and key takeaways
  • Fig. 22 Dopamine agonist market: Application movement analysis
  • Fig. 23 Parkinson's disease market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Restless Legs Syndrome (RLS) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Hyperprolactinemia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Dopamine agonist market: Route of administration outlook and key takeaways
  • Fig. 28 Dopamine agonist market: Route of administration movement analysis
  • Fig. 29 Oral market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Injectable market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Dopamine agonist market: Distribution channel outlook and key takeaways
  • Fig. 33 Dopamine agonist market: Distribution channel movement analysis
  • Fig. 34 Retail pharmacies market estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Other pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Dopamine agonist market revenue, by region, 2024 & 2030, (USD Million)
  • Fig. 38 Regional marketplace: Key takeaways
  • Fig. 39 Regional marketplace: Key takeaways
  • Fig. 40 North America dopamine agonist market estimates and forecasts, 2018 - 2030 ((USD Million)
  • Fig. 41 Key country dynamics
  • Fig. 42 Target disease prevalence
  • Fig. 43 U.S. dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Key country dynamics
  • Fig. 45 Target disease prevalence
  • Fig. 46 Canada dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Mexico dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Key country dynamics
  • Fig. 49 Target disease prevalence
  • Fig. 50 Europe dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Key country dynamics
  • Fig. 52 Target disease prevalence
  • Fig. 53 UK dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Key country dynamics
  • Fig. 55 Target disease prevalence
  • Fig. 56 Germany dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 Target disease prevalence
  • Fig. 59 France dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Key country dynamics
  • Fig. 61 Target disease prevalence
  • Fig. 62 Spain dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Key country dynamics
  • Fig. 64 Target disease prevalence
  • Fig. 65 Italy dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Key country dynamics
  • Fig. 67 Target disease prevalence
  • Fig. 68 Denmark dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Key country dynamics
  • Fig. 70 Target disease prevalence
  • Fig. 71 Sweden dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 Target disease prevalence
  • Fig. 74 Norway dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 Rest of Europe dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Asia Pacific dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Key country dynamics
  • Fig. 78 Target disease prevalence
  • Fig. 79 Japan dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Key country dynamics
  • Fig. 81 Target disease prevalence
  • Fig. 82 China dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Key country dynamics
  • Fig. 84 Target disease prevalence
  • Fig. 85 India dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Key country dynamics
  • Fig. 87 Target disease prevalence
  • Fig. 88 Australia dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 Key country dynamics
  • Fig. 90 Thailand dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 Key country dynamics
  • Fig. 92 South Korea dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 Rest of Asia Pacific dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 94 Latin America dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 95 Key country dynamics
  • Fig. 96 Target disease prevalence
  • Fig. 97 Brazil dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 98 Key country dynamics
  • Fig. 99 Target disease prevalence
  • Fig. 100 Argentina dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 101 Rest of Latin America dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 102 MEA dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 103 Key country dynamics
  • Fig. 104 Target disease prevalence
  • Fig. 105 South Africa dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 106 Key country dynamics
  • Fig. 107 Target disease prevalence
  • Fig. 108 Saudi Arabia dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 109 Key country dynamics
  • Fig. 110 Target disease prevalence
  • Fig. 111 UAE dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 112 Key country dynamics
  • Fig. 113 Target disease prevalence
  • Fig. 114 Kuwait dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 115 Rest of MEA dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)